Odyssey outcomes study
Study / Research
A clinical trial led by John Kastelein that helped establish the safety and efficacy of PCSK9 inhibitors.
Mentioned in 2 videos
Save the 2 videos on Odyssey outcomes study to your own pod.
Sign up free to keep building your knowledge base on Odyssey outcomes study as more episodes are added.
Videos Mentioning Odyssey outcomes study
255-Latest therapeutics in CVD, APOE’s role in Alzheimer’s disease, familial hypercholesterolemia
Peter Attia MD
A clinical trial led by John Kastelein that helped establish the safety and efficacy of PCSK9 inhibitors.
407 ‒ Preventing cardiovascular and Alzheimer’s disease: lowering LDL early, APOE4, and more
Peter Attia MD
Trial for Praluent (PCSK9 inhibitor) where benefit was observed after two years, even in patients with already low LDL.